Back to Search
Start Over
The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
- Source :
- Therapeutic Advances in Cardiovascular Disease; Aug2009, Vol. 3 Issue 4, p309-315, 7p
- Publication Year :
- 2009
-
Abstract
- CRP levels are strong, independent predictors of cardiovascular risk and can enhance risk stratification. Jupiter enrolled 17 802 apparently healthy middle-aged men and women with CRP levels over 2.0 mg/l, and LDL less than 130 mg/dl. They were randomized to receive rosuvastatin 20 mg daily or placebo, and followed for a primary endpoint of nonfatal myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or cardiovascular death for 1.9 years. Rosuvastatin lowered CRP (37%), LDL (50%), nonfatal myocardial infarction (55%), nonfatal stroke (48%), hospitalization and revascularization (47%), all-cause mortality (20%), and benefited women and minority subgroups. Rosuvastatin was tolerated relatively well, with a small rise in physician-reported diabetes. Jupiter data suggest that patients with high levels of CRP should receive statins. Approximately 4.3% of the population satisfies Jupiter inclusion criteria. A review of the assessment of cardiovascular risk is under way at the National Institutes of Health to guide practitioners. [ABSTRACT FROM PUBLISHER]
Details
- Language :
- English
- ISSN :
- 17539447
- Volume :
- 3
- Issue :
- 4
- Database :
- Complementary Index
- Journal :
- Therapeutic Advances in Cardiovascular Disease
- Publication Type :
- Academic Journal
- Accession number :
- 53124056
- Full Text :
- https://doi.org/10.1177/1753944709337056